Skip to content
Trial Eligibility
Menu

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

NCT07775534

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Glioblastoma

Eligibility basics and study details

Study type
Interventional
Phase
Not applicable
Ages
18 years and older
Sex
All
Healthy volunteers
Accepted
Sponsor
City of Hope Medical Center
Last updated on ClinicalTrials.gov
October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 1

  • City of Hope Medical Center · Duarte, CA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.